Molecular-Targeted Therapies for Hematologic Malignancies

田蕙芬（2003）。Molecular Therapy in Hematologic Malignancies。台灣醫學，7(2)，212-221。https://doi.org/10.6320/FJM.2003.7(2).09
Belay, Y., Yirdaw, K., & Enawgaw, B. (2017). Tumor Lysis Syndrome in Patients with Hematological Malignancies. Journal of Oncology, 2017(), 1-9-011. https://doi.org/10.1155/2017/9684909
McDaniel, J. M., Ibarz, J. P., & Burnette, P. K. E. (2012). Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies. Advances in Hematology, 2012(), 332-340. https://doi.org/10.1155/2012/513702
Yau, C. C. (2012). Molecular targeted therapies in advanced hepatocellular carcinoma [master's thesis, The University of Hong Kong]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0029-1812201200020596
Bais, S., Bartee, E., Rahman, M. M., McFadden, G., & Cogle, C. R. (2012). Oncolytic Virotherapy for Hematological Malignancies. Advances in Virology, 2012(), 54-61. https://doi.org/10.1155/2012/186512